SCHEMBL1830233

SCHEMBL1830233

O=C1[N]CCCC1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
HSD11B1 P28845 2/20 0.44
CYP19A1 P11511 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
MAOB P27338 1/20 0.40
F2 P00734 2/20 0.39
PRSS1 P07477 2/20 0.39
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
POLB P06746 1/20 0.38
GBA1 P04062 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
CES2 O00748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1831263 0.89 DDB1 (0.47) DDB1CRBNHSD11B1CYP19A1NPC1
SCHEMBL1831946 0.78 DDB1 (0.46) DDB1CRBNHSD11B1CYP19A1NPC1
SCHEMBL19050135 0.76 DDB1 (0.51) DDB1CRBNHSD11B1ALDH1A1MAOB
SCHEMBL8676314 0.76 DDB1 (0.51) DDB1CRBNHSD11B1ALDH1A1MAOB
SCHEMBL8676485 0.76 DDB1 (0.51) DDB1CRBNHSD11B1ALDH1A1MAOB
SCHEMBL11790156 0.74 HSD11B1 (0.57) DDB1CRBNHSD11B1ALDH1A1MAOB
SCHEMBL23056654 0.73 PTGS2 (0.59) DDB1CRBNHSD11B1CYP19A1KMT2A
SCHEMBL793526 0.73 PTGS2 (0.59) DDB1CRBNHSD11B1CYP19A1KMT2A
SCHEMBL29169544 0.73 PTGS2 (0.59) DDB1CRBNHSD11B1CYP19A1KMT2A
SCHEMBL9790769 0.71 PTGS2 (0.57) DDB1CRBNHSD11B1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 EP claimed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 WO claimed
US-20180340174-A1 METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS NANOCORE APS (DK) 2018-11-29 US disclosed
EP-3218479-A1 METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS Nanocore ApS (DK) 2017-09-20 EP disclosed
WO-2016074683-A1 METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS LUNDORF PEDERSEN MATERIALS APS (DK) 2016-05-19 WO disclosed
US-20110230419-A1 IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2011-09-22 US disclosed
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 EP disclosed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230419-A1 IAP BINDING COMPOUNDS BIRC5, BIRC7, BIRC3 DDB1 163/4885CRBN 2397/4885HSD11B1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.